ABCG2 and glioblastoma: For example, GBM patients may also potentially benefit from therapies targeting ABCG2; indeed, some anti-ABCG2 therapies have been recently tested in preclinical and clinical contexts [46,47,48,49,50,51,52,53] and could prove more efficacious in targeting Fluo+ GSCs.